MSAM
ADPT icon

Moloney Securities Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Moloney Securities Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,000
Closed -$90.5K – 484
2024
Q2 		$90.5K Sell
25,000
-45,240
-64% -$144K 0.01% 445
2024
Q1 		$225K Buy
+70,240
New +$272K 0.03% 394

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Moloney Securities Asset Management's ADPT Position: Q3 2024 in Review

Moloney Securities Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2024, closing a stake of 25,000 shares — an estimated $90.5K sold.

Moloney Securities Asset Management first reported a position in ADPT in Q1 2024 and held it in 2 quarters. The position peaked at $225K in Q1 2024. 187 funds tracked by Wall St. Rank hold ADPT as of Q3 2024.

  • Moloney Securities Asset Management reported no remaining Adaptive Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Moloney Securities Asset Management sold 25,000 Adaptive Biotechnologies shares in Q3 2024, an estimated $90.5K.
  • Moloney Securities Asset Management first reported a position in Adaptive Biotechnologies in Q1 2024 and held it in 2 quarters.
  • Moloney Securities Asset Management's Adaptive Biotechnologies position peaked at $225K in Q1 2024.
  • 187 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2024.

Based on Moloney Securities Asset Management's 13F filing for Q3 2024, filed 30 Oct 2024.